Demographic and clinical details of the patients with RA and SpA included in the study
| Patient No | Age (years) | Sex (M/F) | Disease duration (months) | Drug treatment | CRP (mg/l) | RF (+/−) | HLA B27 (+/−) | Erosions (+/−) |
|---|---|---|---|---|---|---|---|---|
| CRP, C reactive protein: RF, rheumatoid factor; RA, rheumatoid arthritis; NSAIDs, non-steroidal anti-inflammatory drugs; MTX, methotrexate; IM gold, intramuscular sodium aurothiomalate; SpA, spondyloarthropathy; SSZ, sulfasalazine; AS, ankylosing spondylitis; AZA, azathioprine. | ||||||||
| Patients with active RA | ||||||||
| RA1 | 76 | M | 2 | NSAIDs | 59 | + | − | |
| RA2 | 72 | M | 3 | NSAIDs | 120 | + | − | |
| RA3 | 65 | M | 9 | Plaquenil | 30 | + | − | |
| RA4 | 75 | F | 3 | NSAIDs | 47 | + | + | |
| RA5 | 47 | M | 3 | NSAIDs | 58 | + | − | |
| RA6 | 61 | F | 2 | NSAIDs | 84 | − | − | |
| RA7 | 75 | M | 2 | NSAIDs | 20 | − | − | |
| RA8 | 86 | M | 6 | NSAIDs | 76 | − | − | |
| RA9 | 78 | F | 3 | NSAIDs | 27 | + | + | |
| RA10 | 31 | F | 6 | NSAIDs | 32 | + | − | |
| RA11 | 67 | F | 2 | Prednisolone | 307 | − | − | |
| RA12 | 76 | F | 4 | NSAIDs | 89 | − | − | |
| RA13 | 77 | M | 3 | NSAIDs | 62 | + | − | |
| RA14 | 74 | F | 4 | NSAIDs | 46 | + | + | |
| RA15 | 70 | M | 2 | NSAIDs | 116 | + | + | |
| RA16 | 76 | F | 2 | NSAIDs | 32 | − | − | |
| RA17 | 59 | F | 4 | Plaquenil | 82 | − | − | |
| RA18 | 49 | F | 10 | NSAIDs | 35 | − | + | |
| RA19 | 28 | F | 2 | Sulphasalazine | 37 | − | − | |
| RA20 | 68 | M | 5 | NSAIDs | 34 | + | + | |
| RA21 | 62 | M | 2 | NSAIDs | 28 | − | − | |
| Patients with inactive RA | ||||||||
| RA1 | 78 | M | 30 | MTX | <1 | − | − | |
| RA2 | 79 | M | 24 | IM gold | 5 | + | − | |
| RA3 | 75 | F | 16 | MTX | <1 | + | − | |
| RA4 | 73 | M | 34 | IM gold | <1 | + | − | |
| RA5 | 60 | F | 7 | IM gold | <1 | − | − | |
| RA6 | 63 | M | 8 | Plaquenil | <1 | − | − | |
| RA7 | 79 | M | 27 | SSZ | 2 | + | − | |
| RA8 | 76 | F | 14 | IM gold | 5 | − | + | |
| RA9 | 68 | M | 36 | IM gold/ MTX | 7 | + | + | |
| Patients with SpA | ||||||||
| SpA1 | 26 | F | 36 | NSAIDs | 22 | − | Psoriatic arthritis | |
| SpA2 | 60 | F | 96 | SSZ | 58 | − | Psoriatic arthritis | |
| SpA3 | 28 | F | 24 | SSZ | 13 | + | Reiter's | |
| SpA4 | 43 | F | 192 | NSAIDs | 48 | + | Reiter's | |
| SpA5 | 33 | M | 168 | NSAIDs | 45 | + | Reactive arthritis | |
| SpA6 | 40 | M | 24 | NSAIDs | 13 | − | Psoriatic arthritis | |
| SpA7 | 49 | F | 60 | NSAIDS | 45 | − | Psoriatic arthritis | |
| SpA8 | 65 | M | 56 | NSAIDs | 26 | − | Psoriatic arthritis | |
| SpA9 | 75 | M | 8 | NSAIDs | 94 | + | AS | |
| SpA10 | 73 | M | 120 | NSAIDs | 73 | + | AS | |
| SpA11 | 63 | F | 6 | SSZ/AZA/prednisolone | 52 | + | Colitic arthritis | |
| SpA12 | 30 | M | 72 | SSZ/NSAIDs | 34 | + | AS | |